Cargando…
From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses
Oncolytic viruses constitute an emerging strategy in immunomodulatory cancer treatment. The first oncolytic virus, Talimogene laherparepvec (T-VEC), based on herpes simplex virus 1 (HSV-1), was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2015. The field...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288254/ https://www.ncbi.nlm.nih.gov/pubmed/32542113 http://dx.doi.org/10.1038/s41420-020-0284-1 |